The Business Research Company’s Once-Weekly Basal Insulin Therapy Global Market Report 2026 – Market Size, Trends, And Forecast 2026-2035
LONDON, GREATER LONDON, UNITED KINGDOM, July 26, 2026 /EINPresswire.com/ — The landscape of diabetes treatment is evolving with significant advancements in insulin therapies designed to improve patient convenience and adherence. One such innovation, once-weekly basal insulin therapy, is rapidly gaining attention for its potential to simplify diabetes management through less frequent dosing. Let’s explore the market size, growth drivers, regional dynamics, and emerging trends shaping this promising sector.
Market Expansion and Projections for Once-Weekly Basal Insulin Therapy
The market for once-weekly basal insulin therapy has seen rapid growth in recent years. It is projected to increase from $3.4 billion in 2025 to $3.87 billion in 2026, reflecting a compound annual growth rate (CAGR) of 13.7%. This historical expansion has been driven by the predominance of daily basal insulin injection regimens, the limited lifespan of early insulin analogs, challenges with patient adherence to frequent injections, the complex nature of traditional glucose monitoring systems, and the absence of once-weekly therapy alternatives.
Download a free sample of the once-weekly basal insulin therapy market report:
https://www.thebusinessresearchcompany.com/sample_request?id=38626630&type=smp&name=Once-Weekly%20Basal%20Insulin%20Therapy%20Market%20Report%202026&utm_source=EINPresswire&utm_medium=Paid&utm_campaign=Jul_PR
Looking ahead, this market is expected to continue its robust growth trajectory, reaching $6.51 billion by 2030 at an even higher CAGR of 13.9%. Factors contributing to this surge include the shift toward ultra long-acting insulin formulations, growing demand for patient-centered diabetes management approaches, expansion of home-based and decentralized care models, advancements in sustained-release insulin technologies, and broader adoption of basal insulin intensification protocols. Key trends anticipated during this period involve the development of ultra-long-acting once-weekly basal insulin analogs, enhanced patient adherence through reduced injection frequency, increased use of prefilled pens and auto-injector delivery systems, clinical efforts to minimize hypoglycemia risk while improving glycemic stability, and the rising popularity of homecare diabetes management solutions.
Understanding Once-Weekly Basal Insulin Therapy and Its Benefits
Once-weekly basal insulin therapy is a long-acting insulin treatment designed to regulate blood glucose levels in individuals with diabetes by requiring just one injection per week. This approach provides steady basal insulin coverage to maintain stable blood sugar throughout the week. The therapy aims to reduce the number of injections needed, thereby improving patient compliance and simplifying the overall management of diabetes compared to traditional daily basal insulin regimens.
View the full once-weekly basal insulin therapy market report:
https://www.thebusinessresearchcompany.com/report/once-weekly-basal-insulin-therapy-market-report?utm_source=EINPresswire&utm_medium=Paid&utm_campaign=Jul_PR
How Rising Global Diabetes Prevalence Supports Market Growth
One of the primary factors fueling the expansion of the once-weekly basal insulin therapy market is the increasing prevalence of diabetes worldwide. The number of people living with diabetes continues to rise due to factors like growing obesity rates and aging populations, which contribute to higher incidence rates. Once-weekly basal insulin therapy addresses this expanding patient base by offering long-lasting blood glucose control with fewer injections, which in turn supports better treatment adherence and patient convenience. For example, in April 2025, the International Diabetes Federation reported that 589 million adults aged 20–79 were living with diabetes globally in 2024, with projections suggesting this number will rise to 853 million by 2050. This growing prevalence is a key driver behind the market’s positive outlook.
The Impact of Rising Obesity Rates on Market Demand
Another significant growth driver is the escalating rate of obesity worldwide, which increases the risk of diabetes and related metabolic conditions. Obesity is characterized by excessive fat accumulation and is linked to unhealthy diets, sedentary lifestyles, and low physical activity levels globally. The rising number of obese individuals is thus contributing to greater demand for effective diabetes management solutions like once-weekly basal insulin therapy. This treatment offers improved blood glucose control with reduced injection frequency, enhancing adherence and convenience for patients. According to the World Obesity Federation in March 2024, the adult population living with obesity is expected to grow from 1.01 billion in 2025 to 1.53 billion by 2035. This trend further supports market growth in this therapy segment.
Regional Leadership and Growth Prospects in Once-Weekly Basal Insulin Therapy
In 2025, North America held the largest share of the once-weekly basal insulin therapy market, demonstrating strong adoption and established healthcare infrastructure. Meanwhile, Asia-Pacific is forecasted to be the fastest-growing region over the upcoming years, driven by increasing diabetes prevalence, improving healthcare access, and expanding treatment awareness. The broader market analysis also encompasses regions including South East Asia, Western Europe, Eastern Europe, South America, the Middle East, and Africa, providing a comprehensive global perspective on market dynamics.
Our 2026 market reports now include enhanced strategic insights through:
• Market attractiveness scoring and analysis
• Total addressable market (TAM) analysis
• Company scoring matrix graphics and tables
• Excel-based forecasting dashboards
• Market hotspots infographics
• Key technologies and future trend analysis
• Updated graphics and tables
Learn More About The Business Research Company
With over 30,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Europe +44 7882 955267
Asia & Others +44 7882 955267 & +91 8897263534
Email us at marketing@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Oliver Guirdham
The Business Research Company
+44 7882 955267
info@tbrc.info
Visit us on social media:
LinkedIn
Facebook
X
Legal Disclaimer:
EIN Presswire provides this news content “as is” without warranty of any kind. We do not accept any responsibility or liability
for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this
article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
Media gallery
